Author: Saahir Khan; Rie Nakajima; Aarti Jain; Rafael Ramiro de Assis; Al Jasinskas; Joshua M. Obiero; Oluwasanmi Adenaiye; Sheldon Tai; Filbert Hong; Donald K. Milton; Huw Davies; Philip L. Felgner
Title: Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray Document date: 2020_3_25
ID: lw12h047_13
Snippet: A coronavirus antigen microarray has been constructed with antigens from epidemic coronaviruses including SARS-CoV-2 and common human coronaviruses, in addition to other common respiratory viruses. A pilot study of 5 naïve human sera shows high IgG seroreactivity to common human coronaviruses but low IgG seroreactivity to SARS-CoV-2, with some cross-reactivity seen for S2 domain of spike protein and nucleocapsid protein. Further studies are need.....
Document: A coronavirus antigen microarray has been constructed with antigens from epidemic coronaviruses including SARS-CoV-2 and common human coronaviruses, in addition to other common respiratory viruses. A pilot study of 5 naïve human sera shows high IgG seroreactivity to common human coronaviruses but low IgG seroreactivity to SARS-CoV-2, with some cross-reactivity seen for S2 domain of spike protein and nucleocapsid protein. Further studies are needed including with SARS-CoV-2 convalescent sera to fully realize the potential of this novel methodology to characterize the seroprevalence of SARS-CoV-2 and the impact of pre-existing cross-reactive antibodies on the disease course.
Search related documents:
Co phrase search for related documents- common respiratory virus and disease course: 1, 2, 3, 4, 5
- common respiratory virus and nucleocapsid protein: 1
- common respiratory virus and pilot study: 1
- common respiratory virus and respiratory virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- common respiratory virus and spike protein: 1, 2
- cross reactive antibody and human sera: 1, 2
- cross reactive antibody and nucleocapsid protein: 1
- cross reactive antibody and pre existing cross reactive antibody: 1, 2
- cross reactive antibody and respiratory virus: 1, 2, 3, 4, 5
- cross reactive antibody and SARS convalescent: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cross reactive antibody and SARS convalescent sera: 1, 2
- cross reactive antibody and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9
- disease course and human sera: 1, 2, 3
- disease course and novel methodology: 1
- disease course and nucleocapsid protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- disease course and nucleocapsid protein spike protein: 1, 2, 3, 4, 5, 6
- disease course and pilot study: 1, 2, 3, 4, 5, 6, 7, 8, 9
- disease course and respiratory virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- disease course and SARS convalescent: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Co phrase search for related documents, hyperlinks ordered by date